



Dyne Therapeutics Expands Board of Directors with Appointment of Lawrence Klein

August 19, 2019

CAMBRIDGE, Mass.— [Dyne Therapeutics](#), a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Lawrence Klein, Ph.D., to its Board of Directors.

“Dyne’s FORCE therapeutic platform achieves a unique combination of tissue-specific delivery, high potency and tolerability to enable a broad product pipeline,” said Dr. Klein. “I look forward to working closely with the board and leadership team to execute our growth strategy and explore new partnerships to develop life-transforming therapies.”

“We are pleased to welcome Lawrence to the Board as we rapidly advance our platform of targeted therapies for serious muscle diseases, including DM1, DMD and FSHD,” said Jason P. Rhodes, Dyne executive chairman and partner at Atlas Venture. “Lawrence’s deep experience across both corporate strategy and business development will be invaluable assets as we move through our next phases of growth.”

Dr. Klein is currently chief business officer at CRISPR Therapeutics, where he previously served as vice president of strategy and corporate development. Before joining CRISPR, he was an associate partner at McKinsey & Company, where he was a leader in the biotech practice and served a number of biotech companies on a wide range of topics, from strategy to operations. He received his B.S. in biochemistry and physics from the University of Wisconsin-Madison and his Ph.D. in biophysics from Stanford University.

About Dyne Therapeutics

Dyne Therapeutics is pioneering therapies that target muscle tissue with unprecedented precision to restore muscle health. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle to treat a range of serious muscle diseases. Dyne is advancing a treatment for myotonic dystrophy type 1 (DM1) in addition to programs for Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne launched in 2019 and is based in Waltham, Mass. For more information, please visit www.dyne-tx.com.

Media Contact

Ten Bridge Communications
Max Stendahl, 508-277-8117
max@tenbridgecommunications.com